Literature DB >> 19250697

Doubling time of lung cancer determined using three-dimensional volumetric software: comparison of squamous cell carcinoma and adenocarcinoma.

Osamu Honda1, Takeshi Johkoh, Junko Sekiguchi, Noriyuki Tomiyama, Naoki Mihara, Hiromitsu Sumikawa, Atsuo Inoue, Masahiro Yanagawa, Tadahisa Daimon, Meinoshin Okumura, Hironobu Nakamura.   

Abstract

The aim of the present study was to investigate the difference in doubling time between squamous cell carcinoma (SCC) and adenocarcinoma of solid pulmonary cancer using three-dimensional volumetric software. We included 40 patients with adenocarcinoma and 11 patients with SCC, who underwent CT examinations more than once before surgical treatment. Tumor volumes and doubling times were obtained using three-dimensional volumetric computer software. Statistical analysis was performed using Mann-Whitney's U-test except for negative doubling times (doubling times less than 0 day). Negative doubling time was found in 5 of the 40 adenocarcinomas (13%), but not in any of the patients with SCC. Doubling time was beyond 400 days in 11 of the 40 adenocarcinomas (28%), but was always less than 400 days in SCC. The mean doubling time of SCC was 126+/-58 days (range, 39-221 days; median, 131 days), while that of adenocarcinomas, except for the negative doubling times, was 976+/-3134 days (range, 69-18,678 days; median, 258 days). Doubling time differed significantly between adenocarcinomas and SCC (p<0.01). In conclusion, the median doubling time of SCC lung cancers is less than that of adenocarcinomas, as measured with automated volumetric measurement software.

Entities:  

Mesh:

Year:  2009        PMID: 19250697     DOI: 10.1016/j.lungcan.2009.01.018

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  22 in total

1.  Optimal MRI interval for detection of asymptomatic recurrence in surgically treated early cervical cancer by use of a mathematical model.

Authors:  A Laios; K Gubbala; R Lampe; A Tolis
Journal:  Hippokratia       Date:  2016 Jan-Mar       Impact factor: 0.471

2.  Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome.

Authors:  Allison B Weisbrod; Mio Kitano; Francine Thomas; David Williams; Neelam Gulati; Krisana Gesuwan; Yixun Liu; David Venzon; Ismail Turkbey; Peter Choyke; Jack Yao; Steven K Libutti; Naris Nilubol; William M Linehan; Electron Kebebew
Journal:  J Am Coll Surg       Date:  2013-11-12       Impact factor: 6.113

3.  Volume doubling time of lung cancers detected in a chest radiograph mass screening program: Comparison with CT screening.

Authors:  Maki Kanashiki; Takuji Tomizawa; Iwao Yamaguchi; Koichi Kurishima; Nobuyuki Hizawa; Hiroichi Ishikawa; Katsunori Kagohashi; Hiroaki Satoh
Journal:  Oncol Lett       Date:  2012-06-28       Impact factor: 2.967

4.  Clinically driven design of multi-scale cancer models: the ContraCancrum project paradigm.

Authors:  K Marias; D Dionysiou; V Sakkalis; N Graf; R M Bohle; P V Coveney; S Wan; A Folarin; P Büchler; M Reyes; G Clapworthy; E Liu; J Sabczynski; T Bily; A Roniotis; M Tsiknakis; E Kolokotroni; S Giatili; C Veith; E Messe; H Stenzhorn; Yoo-Jin Kim; S Zasada; A N Haidar; C May; S Bauer; T Wang; Y Zhao; M Karasek; R Grewer; A Franz; G Stamatakos
Journal:  Interface Focus       Date:  2011-03-30       Impact factor: 3.906

5.  Computed tomography surveillance scanning after lung cancer surgery: mathematical optimization of scanning interval based on tumour biology.

Authors:  Michael Poullis
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-11-13

6.  Pulmonary metastasectomy for gastric cancer: a 13-year single-institution experience.

Authors:  Yoshihisa Kobayashi; Takayuki Fukui; Seiji Ito; Kohei Shitara; Simon Ito; Shunzo Hatooka; Tetsuya Mitsudomi
Journal:  Surg Today       Date:  2012-11-27       Impact factor: 2.549

7.  The impact of histology and ground-glass opacity component on volume doubling time in primary lung cancer.

Authors:  Kai Obayashi; Kimihiro Shimizu; Seshiru Nakazawa; Toshiteru Nagashima; Toshiki Yajima; Takayuki Kosaka; Jun Atsumi; Natsuko Kawatani; Tomohiro Yazawa; Kyoichi Kaira; Akira Mogi; Hiroyuki Kuwano
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

8.  Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.

Authors:  Nikolaus B Wagner; Max M Lenders; Kathrin Kühl; Lydia Reinhardt; Fiona André; Milena Dudda; Natalie Ring; Chiara Ebel; Ramon Stäger; Caroline Zellweger; Roland Lang; Michael Paar; Philipp Gussek; Georg Richtig; Suzan H Stürmer; Susanne Kimeswenger; Angela Oellinger; Andrea Forschner; Ulrike Leiter; Benjamin Weide; Maximilian Gassenmaier; Amadeus Schraag; Bernhard Klumpp; Wolfram Hoetzenecker; Carola Berking; Erika Richtig; Mirjana Ziemer; Johanna Mangana; Patrick Terheyden; Carmen Loquai; Van Anh Nguyen; Christoffer Gebhardt; Friedegund Meier; Stefan Diem; Antonio Cozzio; Lukas Flatz; Martin Röcken; Claus Garbe; Thomas K Eigentler
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

9.  Volumetric analysis of the thymic epithelial tumors: correlation of tumor volume with the WHO classification and Masaoka staging.

Authors:  Yukihisa Sato; Masahiro Yanagawa; Akinori Hata; Yukihiro Enchi; Noriko Kikuchi; Osamu Honda; Katsuyuki Nakanishi; Noriyuki Tomiyama
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

10.  Volume doubling time of lung adenocarcinomas considering epidermal growth factor receptor mutation status of exon 19 and 21: three-dimensional volumetric evaluation.

Authors:  Rui Zhang; Bojiang Chen; Yongzhao Zhou; Ping Zhou; Jing Jin; Longchao Zhao; Weimin Li
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.